How CMS plans to fix a major flaw in the 340B drug discount program

The 340B drug discount program has brought unintended consequences — and cost. CMS wants to address that.

美国卫生与公众服务部认为，340B折扣计划让医院通过药品价差获利，推高了用药成本与患者自付额。CMS提议以调查得到的采购成本为依据，在2027年把相关药品的Medicare支付降至ASP减33.4%，预计首年减少45.5亿美元药品支出。